Individual and combined effects of cannabidiol and Δ9-tetrahydrocannabinol on striato-cortical connectivity in the human brain. (June 2022)
- Record Type:
- Journal Article
- Title:
- Individual and combined effects of cannabidiol and Δ9-tetrahydrocannabinol on striato-cortical connectivity in the human brain. (June 2022)
- Main Title:
- Individual and combined effects of cannabidiol and Δ9-tetrahydrocannabinol on striato-cortical connectivity in the human brain
- Authors:
- Wall, Matthew B
Freeman, Tom P
Hindocha, Chandni
Demetriou, Lysia
Ertl, Natalie
Freeman, Abigail M
Jones, Augustus PM
Lawn, Will
Pope, Rebecca
Mokrysz, Claire
Solomons, Daniel
Statton, Ben
Walker, Hannah R
Yamamori, Yumeya
Yang, Zixu
Yim, Jocelyn LL
Nutt, David J
Howes, Oliver D
Curran, H Valerie
Bloomfield, Michael AP - Abstract:
- Background: Cannabidiol (CBD) and Δ 9 -tetrahydrocannabinol (THC) are the two major constituents of cannabis with contrasting mechanisms of action. THC is the major psychoactive, addiction-promoting, and psychotomimetic compound, while CBD may have opposite effects. The brain effects of these drugs alone and in combination are poorly understood. In particular, the striatum is implicated in the pathophysiology of several psychiatric disorders, but it is unclear how THC and CBD influence striato-cortical connectivity. Aims: To examine effects of THC, CBD, and THC + CBD on functional connectivity of striatal sub-divisions (associative, limbic and sensorimotor). Method: Resting-state functional Magnetic Resonance Imaging (fMRI) was used across two within-subjects, placebo-controlled, double-blind studies, with a unified analysis approach. Results: Study 1 ( N = 17; inhaled cannabis containing 8 mg THC, 8 mg THC + 10 mg CBD or placebo) showed strong disruptive effects of both THC and THC + CBD on connectivity in the associative and sensorimotor networks, but a specific effect of THC in the limbic striatum network which was not present in the THC + CBD condition. In Study 2 ( N = 23, oral 600 mg CBD, placebo), CBD increased connectivity in the associative network, but produced only relatively minor disruptions in the limbic and sensorimotor networks. Outcomes: THC strongly disrupts striato-cortical networks, but this effect is mitigated by co-administration of CBD in the limbicBackground: Cannabidiol (CBD) and Δ 9 -tetrahydrocannabinol (THC) are the two major constituents of cannabis with contrasting mechanisms of action. THC is the major psychoactive, addiction-promoting, and psychotomimetic compound, while CBD may have opposite effects. The brain effects of these drugs alone and in combination are poorly understood. In particular, the striatum is implicated in the pathophysiology of several psychiatric disorders, but it is unclear how THC and CBD influence striato-cortical connectivity. Aims: To examine effects of THC, CBD, and THC + CBD on functional connectivity of striatal sub-divisions (associative, limbic and sensorimotor). Method: Resting-state functional Magnetic Resonance Imaging (fMRI) was used across two within-subjects, placebo-controlled, double-blind studies, with a unified analysis approach. Results: Study 1 ( N = 17; inhaled cannabis containing 8 mg THC, 8 mg THC + 10 mg CBD or placebo) showed strong disruptive effects of both THC and THC + CBD on connectivity in the associative and sensorimotor networks, but a specific effect of THC in the limbic striatum network which was not present in the THC + CBD condition. In Study 2 ( N = 23, oral 600 mg CBD, placebo), CBD increased connectivity in the associative network, but produced only relatively minor disruptions in the limbic and sensorimotor networks. Outcomes: THC strongly disrupts striato-cortical networks, but this effect is mitigated by co-administration of CBD in the limbic striatum network. Oral CBD administered has a more complex effect profile of relative increases and decreases in connectivity. The insula emerges as a key region affected by cannabinoid-induced changes in functional connectivity, with potential implications for understanding cannabis-related disorders, and the development of cannabinoid therapeutics. … (more)
- Is Part Of:
- Journal of psychopharmacology. Volume 36:Number 6(2022)
- Journal:
- Journal of psychopharmacology
- Issue:
- Volume 36:Number 6(2022)
- Issue Display:
- Volume 36, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 36
- Issue:
- 6
- Issue Sort Value:
- 2022-0036-0006-0000
- Page Start:
- 732
- Page End:
- 744
- Publication Date:
- 2022-06
- Subjects:
- Cannabinoids -- fMRI -- resting-state -- CBD -- THC -- cannabis
Psychopharmacology -- Periodicals
615.78 - Journal URLs:
- http://jop.sagepub.com/ ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/02698811221092506 ↗
- Languages:
- English
- ISSNs:
- 0269-8811
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20708.xml